LameireN., Van BiesenW., DombrosN., DratwaM., FallerB., GahlG.The referral pattern of patients with ESRD is a determinant in the choice of dialysis modality.Perit Dial Int1997; 17(Suppl 2): S161–6.
4.
Van BiesenW., WiedemannM., LameireN.ESRD treatment: A European perspective.J Am Soc Nephrol1998; 9(Suppl 1): S55–62.
5.
Van BiesenW., voor de LOK groep Nefrologie. Het verwijzingspatroon in Oost en West Vlaanderen van patiünten met terminale nierinsufficiüntie.Tijdschr Geneeskd1998; 54: 1615–21.
SessoR., BelascoA.Late diagnosis of chronic renal failure and mortality on maintenance dialysis.Nephrol Dial Transplant1996; 11: 2417–20.
8.
SlingeneyerA.Multicenter study on patient referral to dialysis [Abstract].Perit Dial Int1998; 18(Suppl 1): S136.
9.
InnesA., RoweP., BurdenP., MorganA.Early deaths on renal replacement therapy: The need for early nephrological referral.Nephrol Dial Transplant1992; 7: 467–71.
10.
CampbellJ., EwigmanB., HosokawaM., Van StoneJ.The timing of referral of patients with end stage renal disease.Dialysis and Transplantation1989; 18: 660–86.
11.
MendelssohnD., Toh KuaB., SingerP.Referral for dialysis in Ontario.Arch Int Med1995; 155: 2473–8.
12.
HoodS., SondheimerJ.Impact of pre-ESRD management on dialysis outcomes: A review.Semin Dial1998; 11: 175–80.
13.
McKenzieJ., MossA., FeestT., StockingC., SieglerM.Dialysis decision making in Canada, the United Kingdom, and the United States.Am J Kidney Dis1998; 31: 12–18.
14.
United States Renal Data System.1996 annual data report.Am J Kidney Dis1996; 28(Suppl 2): S1–165.
15.
KjellstrandC., HylanderB., CollinsA.Mortality on dialysis: On the influence of early start, patient characteristics, and transplantation and acceptance rates.Am J Kidney Dis1990; 15: 483–90.
16.
IfuduO., DawoodM., HomelP., FriedmannE.Excess morbidity in patients starting uremia therapy without prior care by a nephrologist.Am J Kidney Dis1996; 28: 841–5.
17.
IsmailN., NeyraR., HakimR.The medical and economical advantages of early referral of chronic renal failure patients to renal specialists.Nephrol Dial Transplant1998; 13: 246–50.
18.
HakimR., HimmelfarbJ.Hemodialysis access failure: A call to action.Kidney Int1998; 54: 1029–40.
19.
WoodsJ., TurenneM., StrawdermanR., YoungE., HirthR., PortF.Vascular access survival among incident hemodialysis patients in the United States.Am J Kidney Dis1997; 30: 50–7.
20.
MuirheadN., BlyndalK.Potential cost savings of planned dialysis start [Abstract].J Am Soc Nephrol1995; 6: 553.
21.
LevinA., LewisM., MortiboyP., FaberS., HareI., PorterE.Multidisciplinary predialysis programs: Quantification and limitations of their impact on patient outcomes in two Canadian settings.Am J Kidney Dis1997; 29(4): 533–40.
22.
GarellaS.The costs of dialysis in the U.S.A.Nephrol Dial Transplant1997; 12(Suppl 1): 10–21.
23.
JacobsC.The costs of dialysis treatments for patients with end stage renal disease in France.Nephrol Dial Transplant1997; 12(Suppl 1): 29–32.
24.
RasgonS., ChemleskiB., HoS., WidrowL., YeohH., SchwanskowskyL.Benefits of a multidisciplinary predialysis program in maintaining employment among patients on home dialysis. In: KhannaR., ed. Advances in peritoneal dialysis.Toronto: Peritoneal Dialysis Publications, 1996; 12: 132–5.
25.
ClyneN., BjörvellH., KlangB., SundstedtC.Patient education in groups in the predialysis stage results in better adaptation to dialysis [Abstract].J Am Soc Nephrol1996; 7: 1442.
26.
HakimR., LazarusJ.Initiation of dialysis.J Am Soc Nephrol1995; 6: 1319–28.
27.
AhlmenJ., CarlssonL., SchönborgC.Well-informed patients with end stage renal disease prefer peritoneal dialysis to hemodialysis.Perit Dial Int1993; 13(Suppl 2): S196–8.
28.
ColesG., WilliamsJ.What is the place of peritoneal dialysis in the integrated treatment of renal failure?Kidney Int1998; 54: 2234–40.
29.
RottembourgJ., IssadB., GallegoJ., DegouletP., AimeF., GueffafB.Evolution of residual renal function in patients undergoing maintenance hemodialysis or continuous ambulatory peritoneal dialysis.Proc Eur Dial Transplant Assoc1983; 19: 397–403.
30.
LysaghtM.Preservation of residual renal function in maintenance dialysis patients.Perit Dial Int1996; 16: 126–7.
31.
LameireN.The impact of residual renal function on the adequacy of peritoneal dialysis.Nephron1997; 77: 13–28.
32.
LameireN., Van BiesenW.The impact of residual renal function on the adequacy of peritoneal dialysis.Perit Dial Int1997; 17(Suppl 2): S102–10.
33.
ChurchillD.N., TaylorD.W., KeshaviahP.R., and the CANUSA Peritoneal Dialysis Study Group. Adequacy of dialysis and nutrition in continuous peritoneal dialysis: Association with clinical outcomes.J Am Soc Nephrol1996; 7: 198–207.
34.
KabandaA., GoffinE., BernardA., LauwerysR., van Ypersele de StrihouC.Factors influencing serum levels and peritoneal clearances of low molecular weight proteins in continuous ambulatory peritoneal dialysis.Kidney Int1995; 48: 1946–52.
35.
CatizoneL., VigliettaG., CocchiR., DadoneC., De VecchiA., GiangrandeA.Dialysis-related amyloidosis in a large CAPD population. In: KhannaR., ed. Advances in peritoneal dialysis.Toronto: Peritoneal Dialysis Publications, 1995; 11: 213–17.
36.
DiRaimondoC.R., MccarleyP., StoneW.J.Beta-2 microglobulin in peritoneal dialysis patients: Serum levels and peritoneal clearances.Perit Dial Int1988; 8: 43–7.
37.
JadoulM., GarbarC., VanholderR., SennesaelJ., MichelC., RobertA.Prevalence of histological beta2-microglobulin amyloidosis in CAPD patients compared with hemodialysis patients.Kidney Int1998; 54: 956–9.
38.
Lopez–MencheroR., MiguelA., Garcia–RamonR., Perez– ContrerasJ., GirbesV.Importance of residual renal function in continuous ambulatory peritoneal dialysis: Its influence on different parameters of renal replacement treatment.Nephron1999; 83: 219–25.
39.
NiwaT., IseM.Indoxyl sulphate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis.J Lab Clin Med1994; 124: 96–104.
40.
NiwaT., YazawaT., KodamaT., UeharaY., MaedaK., YamadaK.Efficient removal of albumin-bound furancarboxylic acid, an inhibitor of erythropoiesis, by continuous ambulatory peritoneal dialysis.Nephron1990; 56: 241–5.
41.
MotojimaM., NishijimaF., IkomaM., KawamuraT., YoshiokaT., FogoA.B.Role for “uremic toxin” in the progressive loss of intact nephrons in chronic renal failure.Kidney Int1991; 40: 461–9.
42.
BlakeP.Adequacy, nutrition, and clinical outcomes.Perit Dial Int1999; 19(Suppl 2): S16–19.
43.
OreopoulosD.The optimization of continuous ambulatory peritoneal dialysis.Kidney Int1999; 55: 1131–49.
44.
HiroshigeK., YuuK., SoejimaM., TakasugiM., KuroiwaA.Rapid decline of residual renal function in patients on automated peritoneal dialysis.Perit Dial Int1996; 16: 307–15.
45.
HufnagelG., MichelC., QueffeulouG., SkhiriH., DamieriH., MignonF.The influence of automated peritoneal dialysis on the decrease in residual renal function.Nephrol Dial Transplant1999; 14: 1224–8.
46.
McCarthyJ.The use of polysulphone dialyzers slows the rate of intrinsic renal function loss in chronic hemodialysis patients [Abstract].J Am Soc Nephrol1993; 4: 367.
47.
LysaghtM., VoneshE., GotchF., IbelsL., KeenM., LindholmB.The influence of dialysis treatment modality on the decline of remaining renal function.ASAIO Trans1991; 37: 598–604.
48.
DaviesS., PhillipsL., RussellG.Peritoneal solute transport predicts survival on CAPD independently of residual renal function.Nephrol Dial Transplant1998; 13: 962–8.
49.
MujaisS., MayberN., SchulzD., HutchcraftA.Timely initiation of dialysis by DOQI guidelines: Maintenance of residual renal function.Kidney Int1999; 10: 265A.
50.
Van BiesenW., VanholderR., LameireN.Impact of pre-transplantation dialysis modality on patient outcome after renal transplantation: The role of peritoneal dialysis revisited.Perit Dial Int1999; 19: 103–6.
51.
BleyerA., BurkartJ., RussellG., AdamsP.Dialysis modality and delayed graft function after cadaveric renal transplantation.J Am Soc Nephrol1999; 10: 154–9.
Giral–ClasseM., HourmantM., CantarovichD., DantalJ., BlanchoG., DaguinP.Delayed graft function of more than six days strongly decreases long-term survival of transplanted kidneys.Kidney Int1998; 54: 972–8.
54.
SamaniegoM., BaldwinW., SanfilippoF.Delayed graft function: Immediate and late impact.Curr Opin Nephrol Hypertens1997; 6: 533–7.
55.
PassalacquaJ.A., WilandA.M., FinkJ.C., BartlettS.T., EvansD.A., KeayS.Increased incidence of postoperative infections associated with peritoneal dialysis in renal transplant recipients.Transplantation1999; 68: 535–40.
56.
PereiraB., LeveyA.Hepatitis C virus infection in dialysis and renal transplantation.Kidney Int1997; 51: 981–99.
57.
ParfreyP., ForbesR., HutchinsonT.The impact of renal transplantation on the course of hepatitis B liver disease.Transplantation1987; 39: 369–76.
58.
CendorogloM., DraibeS., SilvaA., FerrazM., GranatoC., PereiraC.Incidence and risk factors for hepatitis B virus and hepatitis C virus infection among hemodialysis and CAPD patients: Evidence for environmental transmission.Nephrol Dial Transplant1995; 10: 240–6.
59.
PascualJ., TeruelJ., MateosM.Nosocomial transmission of hepatitis C virus infection in a hemodialysis unit during two years of prospective follow-up [Abstract].J Am Soc Nephrol1992; 3: 386.
60.
JadoulM., ChantalC., van Ypersele de StrihouC.Incidence and risk factors for hepatitis seroconversion in hemodialysis: A prospective study.Kidney Int1993; 44: 1322–6.
61.
StuyverL., ClaeysH., WyseurA., Van ArnhemW., De BeenhouwerH., UytendaeleS.Hepatitis C virus in a hemodialysis unit: Molecular evidence for nosocomial transmission.Kidney Int1996; 49: 889–95.
62.
MillerE., AlterM., TokarsJ.Protective effects of hepatitis B vaccine in chronic hemodialysis patients.Am J Kidney Dis1999; 33: 356–60.
63.
KhanA., BernardiniJ., RaultR., PirainoB.Low seroconversion with hepatitis B vaccination in peritoneal dialysis patients.Perit Dial Int1996; 16: 370–3.
64.
NomotoY., KawaguchiY., OhiraS., YuriT., KuboH., KubotaM.Carpal tunnel syndrome in patients undergoing CAPD: A collaborative study in 143 centers.Am J Nephrol1995; 15: 295–9.
65.
TanS.Y., BaillodR., BrownE., FarringtonK., SoperC., PercyM.Clinical, radiological and serum amyloid P component scintigraphic features of beta2-microglobulin amyloidosis associated with continuous ambulatory peritoneal dialysis.Nephrol Dial Transplant1999; 14: 1467–71.
66.
FanP., SchwabS.Vascular access: Concepts for the 1990s.J Am Soc Nephrol1992; 3: 1–11.
67.
IfuduO., MayersJ., CohenL., PaulH., BrezsnyakW., AvramM.Correlates of vascular access and non-vascular access related hospitalizations in hemodialysis patients.Am J Nephrol1996; 16: 118–23.
68.
De VecchiA., DratwaM., WiedemannM.Healthcare systems and end stage renal disease therapies: An international review. Costs and reimbursement/funding of ESRD therapies.Nephrol Dial Transplant1999; 14(Suppl 6): 31–41.
69.
Van BiesenW., VanholderR., DhondtA.M., VeysN., LameireN.An evaluation of an integrative care approach for the treatment of ESRD patients.J Am Soc Nephrol2000; 11: 116–25.
70.
Van BiesenW., DequidtC., VijtD., VanholderR., LameireN.Analysis of the reasons for transfers between hemodialysis and peritoneal dialysis and their effect on survivals. In: KhannaR., ed. Advances in peritoneal dialysis.Toronto: Peritoneal Dialysis Publications, 1998; 14: 90–4.
71.
MaiorcaR., CancariniG., ZubaniR., CameriniC., ManiliL., BrunoriG.CAPD viability: A long-term comparison with hemodialysis.Perit Dial Int1996; 16: 276–87.
72.
BurtonP.R., WallsJ.Selection-adjusted comparison of life-expectancy of patients on continuous ambulatory peritoneal dialysis, hemodialysis and transplantation.Lancet1987; 1(8542): 1115–19.
73.
LeeH.B., SongK.I., KimJ.H., ChaM.K., ParkM.S.Dialysis in patients with diabetic nephropathy: CAPD versus hemodialysis.Perit Dial Int1996; 16(Suppl 1): S269–74.
74.
MarcelliD., StannardD., ConteF., HeldP., LocatelliF., PortF.ESRD patient mortality with adjustment for comorbid conditions in Lombardy versus the United States.Kidney Int1996; 50: 1013–18.
75.
GentilM., CarriazoA., PavonM., RosadoM., CastilloD., RamosB.Comparison of survival in continuous ambulatory peritoneal dialysis and hospital hemodialysis: A multicentric study.Nephrol Dial Transplant1991; 6: 444–51.
76.
SerkesK., BlaggC., NolphK., VoneshE., ShapiroF.Comparison of patient and technique survival in continuous ambulatory peritoneal dialysis and hemodialysis: A multicenter study.Perit Dial Int1990; 10: 15–19.
77.
MaiorcaR., CancariniG., CameriniC., BrunoriG., ManiliL., MovilliE.Is CAPD competitive with hemodialysis for long-term treatment of uraemic patients?Nephrol Dial Transplant1989; 4: 244–53.
78.
MaiorcaR., VoneshE., CancariniG., CantaluppiA., ManiliL., BrunoriG.A six-year comparison of patient and technique survivals in CAPD and HD.Kidney Int1988; 34: 518–24.
79.
GokalR., BaillodR., BogleS., HuntL., JacubowskiC., MarshF.Multi-center study on outcome of treatment in patients on continuous ambulatory peritoneal dialysis and hemodialysis.Nephrol Dial Transplant1987; 2: 172–8.
80.
HeldP., PaulyM., DiamondL.Survival analysis of patients undergoing dialysis.JAMA1987; 257: 645–50.
81.
HeldP., PortF., TurenneM., GaylinD., HamburgerR., WolfeR.Continuous ambulatory peritoneal dialysis and hemodialysis: Comparison of patient mortality with adjustment for comorbid conditions.Kidney Int1994; 45: 1163–9.
82.
GokalR., KingJ., BogleS., MarshF., OliverD., JakubowskiC.Outcome in patients on continuous ambulatory peritoneal dialysis and hemodialysis: 4-year analysis of a prospective multi-center study.Lancet1987; 2(8568): 1105–9.
83.
PortF., WolfeR., BloembergenW., HeldP., YoungE.The study of outcomes for CAPD versus hemodialysis patients.Perit Dial Int1996; 16: 628–33.
84.
BloembergenW., PortF., MaugerE., WolfeR.A comparison of mortality between patients treated with hemodialysis and peritoneal dialysis.J Am Soc Nephrol1995; 6: 177–83.
85.
FoleyR., ParfreyP., HarnettJ., KentG., O'DeaR., MurrayD.Mode of dialysis therapy and mortality in end-stage renal disease.J Am Soc Nephrol1998; 9: 267–76.
86.
VoneshE., MoranJ.Mortality in end-stage renal disease: A reassessment of differences between patients treated with hemodialysis and peritoneal dialysis.J Am Soc Nephrol1999; 10: 354–65.
87.
FentonS., SchaubelD., DesmeulesM., MorrisonH., MaoY., CoplestonP.Hemodialysis versus peritoneal dialysis: A comparison of adjusted mortality rates.Am J Kidney Dis1997; 30: 334–42.
88.
DaviesS., PhillipsL., GriffithsA., RussellL., NaishP., RussellG.What really happens to people on long-term peritoneal dialysis?Kidney Int1998; 54: 2207–17.
89.
CanaudB., MionC.Place de la dialyse péritonéale continue ambulatoire au sein d'un programme de traitement de l'insuffisance rénale chronique. Problèmes posés par les transferts de DCPA en transplantation ou en hémodialyse.Nephrologie1995; 16: 129–35.
90.
SinghS., YiumJ., MaconE., ClarkE., SchafferD., TeschanP.Multicenter study of change in dialysis therapy: Maintenance hemodialysis to continuous ambulatory peritoneal dialysis.Am J Kidney Dis1992; 19: 246–51.
91.
Diaz–BuxoJ.A., GotchF.A., FoldenT.I., RosenblumS., ZazraJ., LewN.Peritoneal dialysis adequacy: A model to assess feasibility with various modalities.Kidney Int1999; 55: 2493–501.
92.
WoodrowG., TurneyJ., BrownjohnA.Technique failure in peritoneal dialysis and its impact on patient survival.Perit Dial Int1997; 17: 360–4.
93.
CollinsA.J., HaoW., XiaH., EbbenJ.P., EversonS.E., ConstantiniE.G.Mortality risks of peritoneal dialysis and hemodialysis.Am J Kidney Dis1999; 34: 1065–74.
94.
KhanI.Survival on renal replacement therapy in Europe: Is there a “center effect”?Nephrol Dial Transplant1996; 11: 300–7.
95.
PirainoB.Peritonitis as a complication of peritoneal dialysis.J Am Soc Nephrol1998; 10: 1956–64.
96.
TopleyN.Biocompatibility of peritoneal dialysis solutions and host defense.Adv Ren Replace Ther1996; 3: 309–11.
97.
ColesG.A.Biocompatibility of various osmotic solutes.Perit Dial Int1995; 15(Suppl 1): S71–5.
98.
LameireN., MatthysD., MatthysE., BeheydtR., RingoirS.Effects of longterm CAPD on carbohydrate and lipid metabolism.Clin Nephrol1988; 30: S53–8.
99.
VanholderR., LameireN., WaterloosM.A., Van LandschootN., De SmetR., VogeleereP.Disturbed host defense in peritoneal cavity during CAPD: Characterization of responsible factors in dwell fluid.Kidney Int1996; 50: 643–52.
100.
SchambyeH.Effect of different buffers on the biocompatibility of CAPD solutions.Perit Dial Int1996; 16(Suppl 1): S130–6.
101.
KredietR.T., DoumaC.E., Ho-dac-PannekeetM.M., ImholzA.L., ZemelD., ZweersM.M.Impact of different dialysis solutions on solute and water transport.Perit Dial Int1997; 17(Suppl 1): S17–26.
102.
VanholderR.C., LameireN.H.Osmotic agents in peritoneal dialysis.Kidney Int1996; 50(Suppl 56): S86–91.
103.
Ho-dac-PannekeetM.M., AtaseverB., StruijkD.G., KredietR.T.Analysis of ultrafiltration failure in peritoneal dialysis patients by means of standard peritoneal permeability analysis.Perit Dial Int1997; 17: 144–50.
104.
HendriksPMEM, Ho-dac-PannekeetM.M., van GulikT.M., StruijkD.G., PhoaSSKS, SieL.Peritoneal sclerosis in chronic peritoneal dialysis patients: Analysis of clinical presentation, risk factors, and peritoneal transport kinetics.Perit Dial Int1997; 17: 136–43.
105.
Van BiesenW., VanholderR., VogelaersD., PelemanR., VerschraegenG., VijtD.The need for a center-tailored treatment protocol for peritonitis.Perit Dial Int1998; 18: 274–81.
106.
International Society for Peritoneal Dialysis, Advisory Committee on Peritonitis Management.Peritoneal dialysis-related peritonitis treatment recommendations: 1996 update.Perit Dial Int1996; 16: 557–73.
107.
Van BiesenW., VanholderR., LameireN.Recent developments in osmotic agents for peritoneal dialysis.Adv Ren Replace Ther1998; 5: 218–31.
108.
LameireN., Van BiesenW., VanholderR.Consequences of using glucose as osmotic agent for peritoneal dialysis.Semin Dial1998; 11: 271–5.
109.
LambE.J., CattellW.R., DawnayA.B.In vitro formation of advanced glycation end products in peritoneal dialysis fluid.Kidney Int1997; 47: 1768–74.
110.
DawnayA.B., MillarD.J.Glycation and advanced glycation end-product formation with icodextrin and dextrose.Perit Dial Int1997; 17: 21–8.
111.
KredietR.T., ZweersM.M., Ho-dac-PannekeetM.M., van der WalA.C., SmitW., DoumaC.E.The effect of various dialysis solutions on peritoneal membrane viability.Perit Dial Int1999; 19(Suppl 2): S257–66.
112.
Van BiesenW., FaictD., BoerW., LameireN.Further animal and human experience with a 0.6% amino acid/ 1.4% glycerol peritoneal dialysis solution.Perit Dial Int1997; 17(Suppl 2): S56–62.
113.
LameireN., Van BiesenW., Van LandschootM., WangT., HeimbürgerO., BergströmJ.Experimental models in peritoneal dialysis: A European experience.Kidney Int1998; 54: 2194–206.